PhosLo
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
General Information
PhosLo, in both capsule and gelcap formulations, has been
approved for the control of hyperphosphatemia in end stage renal
failure in adult patients. Patients suffering from kidney disease
may experience increased blood levels of phosphate, which plays a
pivotal role in causing secondary hyperpara-thyroidism associated
with osteodystrophy and soft-tissue calcification. The rate of
removal of phosphate by dialysis or by dietary manipulation is
insufficient.
Clinical Results
Studies have confirmed that using calcium acetate as a
phosphorus binder will control serum phosphorus levels in most
dialysis outpatients.
Side Effects
Adverse events associated with the use of PhosLo capsules or
gelcaps may include (but are not limited to) the following:
- Nausea
- Constipation
- Vomiting
- Stomach pains
- Anorexia
Mechanism of Action
PhosLo (calcium acetate) binds to the phosphate taken in through
one's diet to form insoluble calcium phosphate. This is then
excreted from the body without being absorbed.
Additional Information
